How to reconstitute hyaluronidase (Hyalase)

Hyaluronidase is an enzyme that hydrolyses hyaluronic acid, breaking the glycosidic linkages of the polymer chain and reducing tissue viscosity. In aesthetic practice it is the only agent capable of degrading hyaluronic acid filler, and it therefore occupies a position no other product does: it is both the correction tool for an unsatisfactory elective result and the emergency treatment for vascular occlusion. It is supplied as a lyophilised powder and must be reconstituted with a diluent before use.

Why concentration governs tissue contact

The enzyme acts only on the substrate it physically reaches. Two variables therefore determine effect: the quantity of enzyme, and the volume of fluid in which it is delivered. These are not the same thing, and the distinction is the whole of the reconstitution question.

A given quantity of enzyme dissolved in a small volume produces a concentrated solution with limited spread — high enzyme density delivered to a small, defined territory. The same quantity dissolved in a large volume produces a dilute solution that distributes further through the tissue, contacting more substrate at lower local concentration. Neither is inherently correct. Discrete correction of a well-defined nodule and flooding of an entire ischaemic vascular territory are different problems with different requirements for spread, and reconstitution is where that decision is made.

Elective versus emergency preparation

In elective correction the goal is controlled, limited degradation: removing or softening a specific deposit while leaving adjacent tissue and native hyaluronic acid as undisturbed as reasonably possible. Precision matters more than reach, and the situation permits deliberation, review and staged reassessment over days.

Emergency use for vascular occlusion inverts every one of these priorities. The aim is to saturate the entire affected vascular territory, since the exact site of the obstruction is not known and the enzyme must reach intraluminal material through the vessel wall and surrounding tissue. Published guidance on the management of hyaluronic acid filler-induced vascular occlusion describes flooding of the territory rather than targeting a point. Systematic review of high-dose pulsed hyaluronidase for impending skin necrosis supports repeated administration until perfusion is restored, rather than a single administration judged sufficient in advance. Published high-dose pulsed protocols and the accompanying safe-use guideline work from a preparation in the region of 1500 units per 1 mL, and that figure is stated here as a description of what appears in the literature, not as a direction for use; the operative principle is that emergency preparation is concentrated because tissue contact across a large field is required quickly.

Availability on the premises

The clearest practical conclusion in the published guidance is not about technique. Occlusion is time-critical, outcomes deteriorate with delay, and there is no route by which hyaluronidase can be obtained from elsewhere within a clinically useful window. Guidance therefore treats immediate availability of adequate quantities of hyaluronidase, on the premises, before any hyaluronic acid treatment begins, as a precondition of proceeding. Reconstitution being a procedure to be worked out under pressure, from an unfamiliar package insert, with a patient in front of you, is itself a foreseeable failure.

Where preparation goes wrong

Recurrent problems include holding a quantity adequate for elective dissolving but not for a territorial emergency; unfamiliarity with the reconstitution arithmetic until the moment it is needed; failure to establish previous exposure and allergy history, since hyaluronidase preparations carry a recognised hypersensitivity risk; and absence of a written protocol, so that the sequence of actions is improvised at the point of greatest time pressure.